SHILPAMED Stock View

Shilpa Medicare Ltd

SHILPAMED Stock View

(NSE)

Trade

₹ 348.6

4.20 | 1.19

Market Cap ₹( Cr.)
30,506.53

Proj. P/E (x)

Proj. P/BV (x)

Proj. ROE (%)

Proj EV / EBITDA (x)
--

Proj. Revenue ( Cr.)

Last Updated On.
17-Sep-2023

 

Copy Link

Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in research and development, manufacturing and sale of oncology drugs and formulations. Its products consist of oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. It supplies oncology APIs and intermediates. Its oncology/non-oncology APIs include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib HCL, and Irinotecan HCL Trihydrate for various regulated markets, including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India. It is also engaged in manufacturing and sale of Lenvatinib Capsules under the brand name Lenshil.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data